Sector News

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

August 7, 2015
Life sciences
Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan’s generics business for $40.5 billion. Mylan’s shares plummeted on that news. And now, Perrigo has broken its silence–and the word isn’t what Mylan wants to hear.
 
Perrigo CEO Joseph Papa stuck to his company’s prior stance that Mylan’s $205-per-share bid “substantially undervalues” its business–and “the market movement following Teva’s announcement last week only reinforced” that conviction, he said during the company’s Q2 earnings call.
 
And if Mylan shareholders vote–at a special meeting later this month–to push forward with the Perrigo deal anyway? “If they proceed with a tender offer for Perrigo, this will not be the easy path that some are painting it to be,” he said, pointing out that the bar for success in the tender offer process is 80% of all outstanding Perrigo shares. ” … We’ll make a strategic decision with the board about what’s the right thing to do for the company,” he said.
 
The way some analysts see it, that’s still a big “if.” As Leerink Partners’ Jason Gerberry wrote in a recent note to investors, Mylan would have to bring its bid to about $230 per Perrigo share to make an “acceptable” offer for its target. And even if it can muster that, the potential tie-up “does not appear to create any value at prices above $205,” Cowen & Co. analyst Ken Cacciatore wrote late last month.
 
Meanwhile, Mylan topped Q2 earnings forecasts Thursday, posting EPS of 91 cents–2 cents better than analysts expected. Revenue of $2.37 billion fell short of analysts’ $2.39 billion forecast, however, despite year-over-year growth of 29%.
 
By Carly Helfand
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach